Publication Date: 25 Apr 2013
Citation: Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2013:7 17-34
This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug in therapy is compared between current worldwide guidelines.
PDF (700.86 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
My experience in publishing my paper in this journal was great. The process was non-complicated and friendly. The editorial team was cooperative and responded promptly and efficiently to my queries. The peer reviewers were professional and fair. Their comments and recommendations added value to my paper. I consider publishing my future research in this journal and recommend it to my colleagues.